BiotechTube

RLYB116 for Injection

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematologic Diseases

Conditions

Hematologic Diseases, Autoimmune Diseases

Trial Timeline

Apr 14, 2025 → Feb 23, 2026

NCT ID
NCT06797375

About RLYB116 for Injection

RLYB116 for Injection is a phase 1 stage product being developed by Rallybio for Hematologic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT06797375. Target conditions include Hematologic Diseases, Autoimmune Diseases.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06797375Phase 1Completed

Competing Products

20 competing products in Hematologic Diseases

See all competitors
ProductCompanyStageHype Score
120 mg LY2784544Eli LillyPhase 2
52
DS3790a + Combination drug + Combination drugDaiichi SankyoPhase 1/2
41
IsavuconazoleAstellas PharmaPhase 2
52
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
DSP-5336 + [14C]-DSP-5336Sumitomo PharmaPhase 1
33
BBI608 + Dexamethasone + Bortezomib + Imatinib + IbrutinibSumitomo PharmaPhase 1
33
Venetoclax + ethinyl estradiol/levonorgestrelAbbViePhase 1
33
ABT-888 + TemozolomideAbbViePhase 1
33
ABBV-101AbbViePhase 1
33
elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injectionAbbViePhase 2
52
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
AZD9829 + AZD9829AstraZenecaPhase 1/2
41
ridaforolimusMerckPhase 2
52
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
Ondansetron + AprepitantMerckPhase 2
52
NemtabrutinibMerckPhase 2
52
ARQ 621MerckPhase 1
33
NemtabrutinibMerckPhase 1
33
PelabresibNovartisPhase 3
77

Other Products from Rallybio

Anti-(integrin beta-3) human monoclonal antibodyPhase 2
44